(Health Korea News / Lee Chang-yong) Merck’s anticancer drug Temeco (ingredient name: tepotinib) and Servier Korea’s acute myeloid leukemia and cholangiocarcinoma treatment Tipsobojeong (ingredient name: ivosidenib) are the first gateway to health insurance coverage. passed.
On the 2nd, the Health Insurance Review and Assessment Service held the ‘2024 7th Severe (Cancer) Disease Deliberation Committee’ and set reimbursement standards for the two drugs for which two companies applied for new drug treatment benefit decisions. However, only part of the indications (efficacy and effect) applied by the company were approved for Tipsobojeong. (see chart below)
Temeco Tablet has been recognized for its efficacy and effectiveness in the treatment of locally advanced or metastatic non-small cell lung cancer with confirmed MET exon 14 skipping.
Tipsovojeong has been recognized for its efficacy and effectiveness in combination with azacitidine in adult patients aged 75 years or older or with comorbidities who are not suitable for intensive induction chemotherapy who are newly diagnosed with IDH1 mutation-positive acute myeloid leukemia. Reimbursement criteria were not recognized for monotherapy in adult patients with locally advanced or metastatic cholangiocarcinoma who were positive for IDH1 mutations and had prior treatment.
In addition, GlaxoSmithKline’s (GSK) endometrial cancer treatment drug Zemperi (ingredient name: dostalimab) is used to treat newly diagnosed progressive or recurrent mismatch repair defects (dMMR) and high-frequency microsatellite instability. -high·MSI-H) Recognized for expansion of coverage for combination therapy with platinum-based chemotherapy as a treatment for adult patients with endometrial cancer.
Kyowa Kirin Korea’s anticancer drug Neurastafree Field Syringe (ingredient name: pegfilgrastim) is also covered for the treatment of febrile neutropenia and reduction of the duration of neutropenia in patients receiving cytotoxic chemotherapy for malignant tumors. We succeeded in expanding the standards.
However, Lilly Korea’s breast cancer treatment Verzenio Tablet (ingredient name: Abemaciclib) did not succeed in expanding the reimbursement standard. The indication applied by the company is for adult patients with early breast cancer with a high risk of recurrence who are hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, and lymph node positive. It was a combination therapy with endocrine therapy as adjuvant treatment.
Drugs that have passed the cancer screening committee will be reviewed by the HIRA’s Pharmaceutical Benefits Review Committee (Pharmaceutical Review Committee), negotiate drug prices with the National Health Insurance Corporation, and pass the Health Insurance Policy Review Committee of the Ministry of Health and Welfare. It can be applied.
(Application for decision on medical care benefits for new drug)
|
division |
Item |
pharmacist |
Efficacy/Effectiveness |
Deliberation result |
|
Nursing care benefits Request for decision |
Temeko Tablet(Tepotinib) |
Merck(main) |
MET exon 14 defect(skipping)this Confirmed locally advanced or Metastatic non-small cell lung cancer treatment |
Salary standard setting |
|
Tip small correction(Ivosidenib) |
Korean Servier (main) |
IDH1 Mutation-positive acute myeloid Newly diagnosed with leukemia, only 75Aged or older or intensive induction not suitable for chemotherapy In adult patients with comorbidities Combination therapy with azacitidine |
Salary standard setting |
|
|
IDH1 mutation positive have previous treatment experience Locally advanced or metastatic cholangiocarcinoma Monotherapy in adult patients |
Salary standard Not set |
|||
|
Salary standard enlargement |
Semperi Province(Dostalimab) |
(main)glaxosMiss Kline |
Newly diagnosed progressive or Recurrent mismatch recovery fault (mismatch repair deficient, dMMR)/ High frequency microsatellite instability (microsatellite instability-high, MSI-H) have endometrial cancer As a treatment for adult patients Combination therapy with platinum-based chemotherapy |
Salary standard setting |
|
Neulastafree Field Syringe (pegfilgrass team) etc. |
Kyowa Koreagiraffe(main) etc. |
Cytotoxicity against malignant tumors Patients receiving chemotherapy Occurrence of febrile neutropenia and Reduces the duration of neutropenia |
Salary standard setting |
|
|
Verzeniojeong(Abemaciclip) |
Korean Lily(you) |
hormone receptors(hormone receptor, HR) positivity, human epithelial cell growth factor receptor 2(human epidermal growth factor receptor 2, HER2) voice, High risk of recurrence of positive lymph nodes have early breast cancer As adjunctive treatment in adult patients Combined use with endocrine therapy |
Salary standard Not set (Endocrine therapy is Partial burden) |
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
